Literature DB >> 23817086

Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis.

Yohei Misumi1, Yukio Ando, Nádia P Gonçalves, Maria J Saraiva.   

Abstract

Transthyretin (TTR)-related amyloidosis is a fatal disorder characterized by systemic extracellular deposition of TTR amyloid fibrils. Mutations in the TTR gene cause an autosomal dominant form of the disease-familial amyloidotic polyneuropathy (FAP). Wild-type (WT) TTR can also form amyloid fibrils in elderly patients with senile systemic amyloidosis. Regression of amyloid deposits in FAP patients who undergo liver transplantation to remove the main source of mutant TTR suggests the existence of mechanisms for the clearance of TTR deposits from the extracellular matrix (ECM), but the precise mechanisms are largely unknown. Because fibroblasts are abundant, playing a central role in the maintenance of the ECM and because the skin is one of the major sites of soluble TTR catabolism, in the present study, we analyzed their role in clearance of TTR aggregates. In vitro studies with a fibroblast cell line revealed that fibroblasts endocytosed and degraded aggregated TTR. Subcutaneous injection of soluble and aggregated TTR into WT mice showed internalization and clearance over time by both fibroblasts and macrophages. Immunohistochemical studies of skin biopsies from V30M patients, asymptomatic carriers, recipients of domino FAP livers as well as transgenic mice for human V30M showed intracellular TTR immunoreactivity in fibroblasts and macrophages that increased with clinical status and with age in transgenic mice. Overall, the present in vitro and in vivo data show that fibroblasts endocytose and degrade TTR aggregates. The function or dysfunction of TTR clearance by fibroblasts may have important implications for the development, progression, and regression of TTR deposition in the ECM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817086     DOI: 10.1038/labinvest.2013.83

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

Review 1.  Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.

Authors:  Laura Obici; Roberta Mussinelli
Journal:  Neurotherapeutics       Date:  2021-11-30       Impact factor: 6.088

2.  Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression.

Authors:  Kyle T Dittloff; Antonio Iezzi; Justin X Zhong; Priya Mohindra; Tejal A Desai; Brenda Russell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-05-21       Impact factor: 5.125

3.  Bifunctional crosslinking ligands for transthyretin.

Authors:  P Patrizia Mangione; Stéphanie Deroo; Stephan Ellmerich; Vittorio Bellotti; Simon Kolstoe; Stephen P Wood; Carol V Robinson; Martin D Smith; Glenys A Tennent; Robert J Broadbridge; Claire E Council; Joanne R Thurston; Victoria A Steadman; Antonio K Vong; Christopher J Swain; Mark B Pepys; Graham W Taylor
Journal:  Open Biol       Date:  2015-09       Impact factor: 6.411

4.  Glial cells in familial amyloidotic polyneuropathy.

Authors:  Nádia P Gonçalves; Susete Costelha; Maria J Saraiva
Journal:  Acta Neuropathol Commun       Date:  2014-12-18       Impact factor: 7.801

5.  Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy.

Authors:  Eleni Fella; Kleitos Sokratous; Revekka Papacharalambous; Kyriacos Kyriacou; Joy Phillips; Sam Sanderson; Elena Panayiotou; Theodoros Kyriakides
Journal:  Front Mol Neurosci       Date:  2017-05-10       Impact factor: 5.639

Review 6.  Amyloid Proteins and Peripheral Neuropathy.

Authors:  Mohammed M H Asiri; Sjoukje Engelsman; Niels Eijkelkamp; Jo W M Höppener
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

7.  Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis.

Authors:  Angela Pucci; Alberto Aimo; Veronica Musetti; Andrea Barison; Giuseppe Vergaro; Dario Genovesi; Assuero Giorgetti; Silvia Masotti; Chiara Arzilli; Concetta Prontera; Luigi Emilio Pastormerlo; Michele Alessandro Coceani; Marco Ciardetti; Nicola Martini; Cataldo Palmieri; Claudio Passino; Claudio Rapezzi; Michele Emdin
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

8.  Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis.

Authors:  Nelson Ferreira; Nádia P Gonçalves; Maria J Saraiva; Maria R Almeida
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

9.  Uncovering the Mechanism of Aggregation of Human Transthyretin.

Authors:  Lorena Saelices; Lisa M Johnson; Wilson Y Liang; Michael R Sawaya; Duilio Cascio; Piotr Ruchala; Julian Whitelegge; Lin Jiang; Roland Riek; David S Eisenberg
Journal:  J Biol Chem       Date:  2015-10-12       Impact factor: 5.157

10.  Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.

Authors:  Genki Suenaga; Tokunori Ikeda; Yoshihiro Komohara; Koutaro Takamatsu; Tatsuyuki Kakuma; Masayoshi Tasaki; Yohei Misumi; Mitsuharu Ueda; Takaaki Ito; Satoru Senju; Yukio Ando
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.